Navigation Links
Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
Date:5/20/2009

BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding planned publications of results from clinical trials with blinatumomab and adecatumumab, the efficacy, safety and intended utilization of our pro
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Quantum computers have yet to materialise. Yet, scientists ... making such computers faster. One such approach relies ... controlled by applying an electric field. A new ... coherently coupled quantum dots (TQDs) with electrical impulses ... for example, should TQDs be used as quantum ...
(Date:7/24/2014)... most natural and synthetic processes prefer to settle ... or energyit is within the realm of non-equilibrium ... constant changes in energy and phases, such as ... conditions allow humans to regulate their body temperature, ... with seismic activity. , But even though ...
(Date:7/24/2014)... Research and Markets has announced ... Analytical Instruments Market 2014-2018" report to their offering. ... Genomics is the study of the gene and its ... and functions of proteomes or sets of proteins by ... involves the mapping of genes and DNA sequencing to ...
(Date:7/24/2014)... July 24, 2014 SRI International has been ... National Institute of Allergy and Infectious Diseases (NIAID), part ... development of potential therapies for HIV infection and AIDS. ... HIV and AIDS and the complications and opportunistic infections ... preventing sexual transmission of HIV. According ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... Richard P. Jones II named Vice President and General Manager ... dispense up to one million prescriptions a week, FRANKLIN ... MHS ), one of the nation,s leading pharmacy benefit,managers, today ... home of world,s largest and most-advanced automated pharmacy,capping a nearly ...
... SYK ) announced that it will host a ... Eastern Time, to discuss the Company,s,operating results for the ... operational update. Operating results for the quarter and year,ended ... that day., Stephen P. MacMillan, President and Chief ...
... of over 100 RNA-related Inventions a Key Step in Establishing ... MDRNA ... Nastech,Pharmaceutical Company Inc. ("Nastech") (Nasdaq: NSTK ) announced today ... and (ii) Nastech,s own intellectual property, as such intellectual,property relates ...
Cached Biology Technology:Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the World's Largest, Most-Advanced Automated Pharmacy 2Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the World's Largest, Most-Advanced Automated Pharmacy 3Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the World's Largest, Most-Advanced Automated Pharmacy 4Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the World's Largest, Most-Advanced Automated Pharmacy 5Stryker to Host Conference Call on January 23, 2008 2Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc. 2Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc. 3Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc. 4Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc. 5
(Date:7/24/2014)... out of York University shows a surprisingly effective way ... fungus: moose saliva (yes moose saliva). , Published ... inhibits a grassendophyte mutualism" shows that moose and reindeer ... a fungus called epichlo festucae that produces the toxin ... , "Plants have evolved defense mechanisms to protect themselves, ...
(Date:7/24/2014)... The University of Texas Health Science Center at Houston ... help Harris County residents whose vision problems cannot be ... corrective lenses, many people with low vision can see ... low vision devices, such as telescopes, magnifiers and electronic ... is using the three-year, $164,645 SightFirst grant from the ...
(Date:7/24/2014)... in the United States, wildland managers often utilize the ... trees (ladder fuels). These cuttings and other post-logging ... danger in order to dispose of the material. To ... often cover all or part of the debris pile ... plastic, in order to keep water out. A recent ...
Breaking Biology News(10 mins):Moose drool inhibits growth of toxic fungus: York U research 2UTHealth Dr. Bhavani Iyer awarded low vision grant 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... WI, JANUARY 5, 2009 Currently, plant testing ... risks from chemical pesticides to nontarget plants requires ... Protection of the plant development and reproduction are ... of animals. Past research conducted by the USEPA ...
... UNDERSTANDING GENETIC AND SOCIOECONOMIC DIFFERENCES,CAREFREE, AZ,FEBRUARY 3-6, 2009 ... ethnic differences in treatment and outcomes among cancer ... the underlying causes and what can be done ... Association for Cancer Research is hosting a collaboration ...
... long suffered an identity crisis. Pop culture heedlessly ... dinosaurs. Even paleontologists assumed that because the creatures flew, they ... legs to take flight. Now comes ... 500 pounds of reptilian heft into flight required pterosaurs to ...
Cached Biology News:American Association for Cancer Research hosts Science of Health Care Disparities Meeting 2Four, three, two, one . . . pterosaurs have lift off 2
... I, ds Qualified is a special preparation of ... for double stranded cleavage of DNA molecules. In ... the enzyme makes double strand breaks at random ... resulting fragments can be controlled by the enzyme ...
... type 14 3C protease from human rhinovirus ... the Novagen brand line of restriction grade ... purified recombinant 6XHis-fusion protein, which recognizes the ... LeuGluValLeuPheGln/GlyPro. The small, 22 KDa size of ...
... Hybaid's unique Electro-4 design allows "4 gels ... it is possible to run 200,samples or ... stacking up to four,horizontal gels. To ensure ... to the number of gels being run. ...
... The IEC Centra CL3 series is ... typical research and clinical applications at ... accessory package includes quick connect rotors ... advanced yet intuitive interface allows you ...
Biology Products: